Innovation and development of generic pharmaceuticals
pharmaphorum
MAY 18, 2023
Innovation and development of generic pharmaceuticals Mike.Hammerton Thu, 05/18/2023 - 10:17 Bookmark this
Generic Pharmaceutical Related Topics 
Global Generic Pharmaceutical Partnering Terms and Agreements Analysis Report 2010-2020 – ResearchAndMarkets.com
BioTech 365
SEPTEMBER 17, 2020
DUBLIN–(BUSINESS WIRE)–The “Global Generic Pharmaceutical Partnering Terms and Agreements 2010-2020” report has been added to ResearchAndMarkets.com’s offering.
Join 32,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
FDA approves Analog and Dipharma’s ANDA for nitisinone capsules
Pharmaceutical Technology
JUNE 1, 2023
Dipharma is a pioneer in developing improved generic pharmaceutical products for rare diseases: our desire to innovate and our engagement do not stop, but every day we continue to seek new and better solutions for patients around the world.”
FDA Approval 
130
130 
KFA-115 by Novartis for Melanoma: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 28, 2023
Novartis overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products.
Most prolific drug patent challengers
Drug Patent Watch
JULY 25, 2024
This chart shows the generic pharmaceutical companies that had the most successful drug patent challenges from 2019 to 2024. Companies that successfully challenge patents on branded drugs are granted…
KFA-115 by Novartis for Malignant Mesothelioma: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 28, 2023
Novartis overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products.
SOHM, Inc., Receives a Mandate for Development, Manufacturing, and Supply Two New topical products.
BioTech 365
AUGUST 4, 2021
the “Company”) (OTC PINK:SHMN), a generic Pharmaceutical, Nutraceutical, and Cosmeceutical company that manufactures and markets generic … Continue reading → Chino Hills, 08/04/2021 / 15:52, CET/CEST – EQS Newswire – Sohm, Inc. CHINO HILLS, CA / ACCESSWIRE / August 4, 2021 / SOHM, Inc.
SOHM, Inc. Announce Company outlook for the year 2021 – Shareholder updates.
BioTech 365
MAY 18, 2021
OTC PINK:SHMN), a generic pharmaceutical, nutraceutical, and cosmeceutical company that manufactures and markets generic drugs covering … Continue reading → Chino Hills, 05/18/2021 / 15:31, CET/CEST – EQS Newswire – Sohm, Inc. CHINO HILLS, CA / ACCESSWIRE / May 18, 2021 / SOHM, Inc.
SOHM RECEIVES SEMI-ANNUAL ORDER FROM PRIVATE LABEL CUSTOMER TO BOOST ANTICIPATED REVENUE FOR 2021
BioTech 365
JUNE 3, 2021
the “Company”) (OTC PINK:SHMN), generic Pharmaceutical, Nutraceutical, and Cosmeceutical company that manufactures and markets generic drugs … Continue reading → Chino Hills, 06/03/2021 / 18:51, CET/CEST – EQS Newswire – Sohm, Inc. CHINO HILLS, CA / ACCESSWIRE / June 3, 2021 / SOHM, Inc.
First Nation Group Announces Launch of Pharmaceuticals Division
BioTech 365
MAY 13, 2021
First Nation Group Announces Launch of Pharmaceuticals Division First Nation Group Announces Launch of Pharmaceuticals Division First Nation Group launches new division, First Nation Pharmaceuticals, offering generic pharmaceutical distribution and supply chain management NICEVILLE, Fla.–(BUSINESS
Amring Pharmaceuticals Inc. Enters into License and Development Agreement with Amzell B.V.
BioTech 365
MARCH 12, 2021
Amring Pharmaceuticals Inc. –(BUSINESS WIRE)–Amring Pharmaceuticals Inc. Amring), a niche brand and generic pharmaceutical company, announced today an … Continue reading → Enters into License and Development Agreement with Amzell B.V. BERWYN, Pa.–(BUSINESS
Licensing 52
52 
Teligent, Inc. Announces Third Quarter 2020 Results
BioTech 365
DECEMBER 31, 2020
NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the … Continue reading → Announces Third Quarter 2020 Results Teligent, Inc. Announces Third Quarter 2020 Results BUENA, N.J., 31, 2020 (GLOBE NEWSWIRE) — Teligent, Inc.
Current and future players in the osteoarthritis market
Pharmaceutical Technology
JULY 28, 2022
The current standards of care (SOCs) in OA focus on symptom management and are made up of generic pharmaceuticals, including nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, antidepressants and intra-articular (IA) injections. There are no disease-modifying drugs currently approved for OA.
Marketing 130
130 
Iptacopan hydrochloride by Novartis for Paroxysmal Nocturnal Hemoglobinuria: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 28, 2023
Novartis overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It was also under development for the treatment of idiopathic/primary membranous nephropathy.
Iptacopan hydrochloride by Novartis for Glomerulonephritis: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 28, 2023
Novartis overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It was also under development for the treatment of idiopathic/primary membranous nephropathy.
Amring Pharmaceuticals Inc. Acquires LYSTEDA®
BioTech 365
DECEMBER 2, 2020
Amring Pharmaceuticals Inc. Acquires LYSTEDA® Amring Pharmaceuticals Inc. –(BUSINESS WIRE)–Amring Pharmaceuticals Inc. Amring), a generic pharmaceutical company, announced entering into an agreement with Ferring International Center S.A. Acquires LYSTEDA® BERWYN, Pa.–(BUSINESS
Teligent Announces Completion of Series D Convertible Note Exchange
BioTech 365
SEPTEMBER 23, 2020
NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, announced the closing of the issuance of approximately $27.5 BUENA, N.J., 23, 2020 (GLOBE NEWSWIRE) — Teligent, Inc.
Why Generic Medicines Are Especially Good for the U.S. Right Now
Drug Channels
SEPTEMBER 10, 2020
Today’s guest post comes from George Keefe, Senior Vice President of External Affairs and Public Policy at Teva Pharmaceuticals. George examines the economic impact of generic pharmaceuticals on the U.S. He argues that the generics industry provides safe, effective, and affordable medicines for many Americans.
Medicine 52
52 
AvKARE Recall: Erectile Dysfunction Drug and Antidepressant Mistakenly Packaged Together
XTalks
DECEMBER 14, 2020
AvKARE, a generics pharmaceutical manufacturer based in Pulaski, Tennessee, has issued a recall on one lot each of its sildenafil 100 mg tablets and trazodone 100 mg tablets due to a packaging “mix-up” in which both drugs were filled into the same bottle. According to AvKARE, the error occurred at a third-party bottle filling facility.
Packaging 98
98 
Most prolific drug patent challengers
Drug Patent Watch
JULY 26, 2022
This chart shows the generic pharmaceutical companies that had the most successful drug patent challenges from 2017 to 2022. Companies that successfully challenge patents on branded drugs are granted six…. The post Most prolific drug patent challengers appeared first on DrugPatentWatch - Make Better Decisions.
Risk adjusted net present value: What is the current valuation of Novartis’s Gevokizumab?
Pharmaceutical Technology
FEBRUARY 18, 2023
Novartis Overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It was under development for renal cell carcinoma as first line therapy.
Most prolific drug patent challengers
Drug Patent Watch
NOVEMBER 9, 2023
This chart shows the generic pharmaceutical companies that had the most successful drug patent challenges from 2018 to 2023. Companies that successfully challenge patents on branded drugs are granted six… The post Most prolific drug patent challengers appeared first on DrugPatentWatch - Make Better Decisions.
Most prolific drug patent challengers
Drug Patent Watch
NOVEMBER 9, 2021
This chart shows the generic pharmaceutical companies that had the most successful drug patent challenges from 2016 to 2021. Companies that successfully challenge patents on branded drugs are granted six…. The post Most prolific drug patent challengers appeared first on DrugPatentWatch - Make Better Decisions.
Meiji Seika Pharma Sets up a New Subsidiary in the US
The Pharma Data
JANUARY 4, 2021
Meiji Seika Pharma, since it launched penicillin in Japan in 1946, has been providing high-quality pharmaceutical products such as antibiotics, antidepressants and antipsychotics in Japan and overseas. Integrated Reports: [link].
Most prolific drug patent challengers
Drug Patent Watch
JULY 26, 2021
This chart shows the generic pharmaceutical companies that had the most successful drug patent challenges from 2016 to 2021. Companies that successfully challenge patents on branded drugs are granted six…. The post Most prolific drug patent challengers appeared first on DrugPatentWatch - Make Better Decisions.
Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation
The Pharma Data
MARCH 22, 2023
1 About Sandoz Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our ambition is to be the world’s leading and most valued generics company. In some cases of autoimmune disease, the immune system damages the body’s own tissues.
FDA Approval 40
40 
AvKARE Recall: Erectile Dysfunction Drug and Antidepressant Mistakenly Packaged Together
XTalks
DECEMBER 14, 2020
AvKARE, a generics pharmaceutical manufacturer based in Pulaski, Tennessee, has issued a recall on one lot each of its sildenafil 100 mg tablets and trazodone 100 mg tablets due to a packaging “mix-up” in which both drugs were filled into the same bottle. According to AvKARE, the error occurred at a third-party bottle filling facility.
Packaging 52
52 
Most prolific drug patent challengers
Drug Patent Watch
JULY 26, 2023
This chart shows the generic pharmaceutical companies that had the most successful drug patent challenges from 2018 to 2023. Companies that successfully challenge patents on branded drugs are granted six… The post Most prolific drug patent challengers appeared first on DrugPatentWatch - Make Better Decisions.
Jubilant Pharma Ltd. and Aavis Pharmaceuticals launch Hydroxychloroquine Sulfate tablets in the U.S. market
The Pharma Data
NOVEMBER 5, 2020
About Jubilant Cadista Pharmaceuticals Inc. Jubilant Cadista Pharmaceuticals Inc. is a rapidly growing generic pharmaceutical company in the United States devoted to discovery, manufacture, sale, and distribution of prescription generic pharmaceutical products.
Marketing 40
40 
Lannett To Report Fiscal 2021 First-Quarter Financial Results, Host Conference Call On Wednesday, November 4
The Pharma Data
OCTOBER 27, 2020
Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications. A playback of the call will be archived and accessible on the same website for at least three months. About Lannett Company, Inc. .
Most prolific drug patent challengers
Drug Patent Watch
NOVEMBER 9, 2022
This chart shows the generic pharmaceutical companies that had the most successful drug patent challenges from 2017 to 2022. Companies that successfully challenge patents on branded drugs are granted six…. The post Most prolific drug patent challengers appeared first on DrugPatentWatch - Make Better Decisions.
Sandoz Application for proposed biosimilar adalimumab’s high concentration formulation accepted by EMA
The Pharma Data
JUNE 17, 2022
About Sandoz Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our ambition is to be the world’s leading and most valued generics company. The adalimumab reference medicine (Humira ®* ) was first approved with an adalimumab concentration of 50 mg/mL.
Medicine 52
52 
Guidance on inventor discovery and “invention story” evidence in Canadian patent actions: Federal Court rules in favour of patentee
Pharma in Brief
SEPTEMBER 19, 2023
The Plaintiffs (Boehringer companies) allege that the Defendants (generic pharmaceutical companies) would infringe six Canadian patents if allowed to market generic empagliflozin products. In defence, the Defendants allege that the patents are invalid.
Regulation 52
52 
Sandoz receives approval by European Commission for Hyrimoz® (adalimumab) high-concentration formulation
The Pharma Data
APRIL 4, 2023
About Sandoz Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our ambition is to be the world’s leading and most valued generics company. The adalimumab reference medicine (Humira ® *) was first approved with an adalimumab concentration of 50 mg/mL.
Medicine 40
40 
Novartis’ Sandoz Launches Biosimilars Awareness Campaign to Improve Biosimilars Adoption Worldwide
XTalks
JUNE 8, 2022
Sandoz is a pioneering leader in generic pharmaceuticals and biosimilars, as Sandoz launched the world’s first biosimilar in Europe in 2006 and won the first biosimilar approval in the US in 2014. Related: Cyltezo Becomes First FDA-Approved Interchangeable Humira Biosimilar.
Most prolific drug patent challengers
Drug Patent Watch
NOVEMBER 8, 2020
This chart shows the generic pharmaceutical companies that had the most successful drug patent challenges from 2015 to 2020. Companies that successfully challenge patents on branded drugs are granted six…. The post Most prolific drug patent challengers appeared first on DrugPatentWatch - Make Better Decisions.
Sandoz announces new global ‘Act4Biosimilars’ initiative, to improve patient access and increase adoption by at least 30% in 30+ countries by 2030
The Pharma Data
MAY 31, 2022
About Sandoz Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our ambition is to be the world’s leading and most valued generics company. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs.
Medicine 52
52 
FDA Approves First Generic of Symbicort to Treat Asthma and COPD
The Pharma Data
MARCH 15, 2022
The FDA regularly takes steps to help guide industry through the development process for generic drug products, including combination products, such as MDIs, that consist of a drug and a device.
FDA Approval 52
52 
Excellence Awards 2022 – Winners Announced!
Pharmaceutical Technology
DECEMBER 22, 2022
The organisation is a non-profit generic pharmaceutical company and has launched its Insulin Initiative, which aims to drive affordability and accessibility for all Americans, regardless of insurance status.
Insulin 130
130 
Sandoz confirms late-stage clinical development plans for proposed biosimilar aflibercept, a key ophthalmology medicine
The Pharma Data
MAY 8, 2021
Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our ambition is to be the world’s leading and most valued generics company. About Sandoz. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs.
Novartis delivers solid Q3 results, with strong growth in Innovative Medicines. Announces strategic review of Sandoz
The Pharma Data
OCTOBER 26, 2021
Sandoz is a global leader in generic pharmaceuticals and biosimilars. Its global portfolio covers all major therapeutic areas with a global market leadership position in biosimilars, generic antibiotics and oncology medicines.
Medicine 52
52 
Thirty years of the Patented Medicines (Notice of Compliance) Regulations
Pharma in Brief
DECEMBER 3, 2023
The Regulations became a moving target for the innovative and generic pharmaceutical industries, being amended seven times between 1998 and 2016. This was often the innovator’s only recourse as innovators were typically unable to appeal unfavourable judgments under the Regulations. Frequent amendments (1998–2016).
Regulation 52
52 
Sandoz announces plans to further strengthen its antibiotics manufacturing setup in Europe
The Pharma Data
MAY 18, 2021
Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our ambition is to be the world’s leading and most valued generics company. About Sandoz. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs.
Sandoz confirms late-stage clinical development plans for proposed biosimilar aflibercept, a key ophthalmology medicine | Novartis
The Pharma Data
MAY 2, 2021
Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our ambition is to be the world’s leading and most valued generics company. About Sandoz. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs.
Let's personalize your content